400 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by nVerses Capital LLC

nVerses Capital LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 400 shares of the company’s stock, valued at approximately $354,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Banque Cantonale Vaudoise grew its holdings in Eli Lilly and Company by 9.9% in the 1st quarter. Banque Cantonale Vaudoise now owns 26,503 shares of the company’s stock valued at $20,617,000 after buying an additional 2,383 shares during the last quarter. Conrad Siegel Investment Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $231,000. Wedmont Private Capital grew its stake in shares of Eli Lilly and Company by 5.6% in the first quarter. Wedmont Private Capital now owns 11,825 shares of the company’s stock worth $8,955,000 after acquiring an additional 627 shares during the last quarter. Grandview Asset Management LLC increased its position in Eli Lilly and Company by 42.4% during the first quarter. Grandview Asset Management LLC now owns 763 shares of the company’s stock worth $593,000 after acquiring an additional 227 shares during the period. Finally, Lantz Financial LLC raised its stake in Eli Lilly and Company by 1.6% during the 1st quarter. Lantz Financial LLC now owns 1,220 shares of the company’s stock valued at $949,000 after purchasing an additional 19 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $917.18 on Friday. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The stock has a market capitalization of $871.69 billion, a PE ratio of 135.08, a PEG ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock’s fifty day moving average is $920.70 and its 200-day moving average is $856.27.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Equities research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on LLY shares. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Barclays upped their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Truist Financial boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $986.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.